TAK-063, a phosphodiesterase 10A inhibitor, modulates neuronal activity in various brain regions in phMRI and EEG studies with and without ketamine challenge.
about
Strategies for Utilizing Neuroimaging Biomarkers in CNS Drug Discovery and Development: CINP/JSNP Working Group Report.TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease.TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia.
P2860
TAK-063, a phosphodiesterase 10A inhibitor, modulates neuronal activity in various brain regions in phMRI and EEG studies with and without ketamine challenge.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
TAK-063, a phosphodiesterase 1 ...... nd without ketamine challenge.
@en
TAK-063, a phosphodiesterase 1 ...... nd without ketamine challenge.
@nl
type
label
TAK-063, a phosphodiesterase 1 ...... nd without ketamine challenge.
@en
TAK-063, a phosphodiesterase 1 ...... nd without ketamine challenge.
@nl
prefLabel
TAK-063, a phosphodiesterase 1 ...... nd without ketamine challenge.
@en
TAK-063, a phosphodiesterase 1 ...... nd without ketamine challenge.
@nl
P2093
P50
P1433
P1476
TAK-063, a phosphodiesterase 1 ...... nd without ketamine challenge.
@en
P2093
Haruhide Kimura
Kazunori Suzuki
Michel Bernanos
Motohisa Suzuki
Yoshiro Tomimatsu
P304
P356
10.1016/J.NEUROSCIENCE.2016.10.006
P407
P577
2016-10-08T00:00:00Z